Navigation Links
Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
Date:5/20/2009

arch program at the University of Cincinnati College of Medicine. "Lurasidone has the potential to be an important new therapeutic option for patients with schizophrenia."

Lurasidone's effect on weight was similar to placebo (median change 0.3 kg for overall lurasidone group vs. 0 kg for placebo) as was its effect on lipid and glucose measures. Lurasidone was also well tolerated with a lower overall discontinuation rate (31%) compared to placebo (43%) and few adverse event-related discontinuations (6% and 2% for the overall lurasidone group and placebo, respectively).

Adverse events seen in the trial were generally mild. The most commonly reported adverse events for lurasidone (greater than 5% and at least twice the rate of placebo) were akathisia (17.6% vs. 3.1% placebo), somnolence (11.7% vs. 5.5%), parkinsonism (6.8% vs. 0), and increased weight (5.1% vs. 2.4%).

"DSP is committed to the development of lurasidone and we look forward to the completion of our phase 3 clinical trial program and submission of a new drug application to the U.S. FDA," said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co., Ltd. "More importantly, we believe that lurasidone will be a valuable new treatment option for patients and physicians in addressing currently unmet needs in the treatment of schizophrenia."

"The development program for lurasidone is intended to establish efficacy for the core symptoms of schizophrenia, characterize its safety profile and explore its effects in the treatment of cognitive impairment and other areas not adequately addressed by current therapies," said Antony Loebel, M.D., vice president of clinical research, Dainippon Sumitomo Pharma America, Inc. "As a large, global trial, the PEARL 1 study is an important new addition to the existing clinical trial database."

PEARL 1 Study Design

This randomized, placebo
'/>"/>

SOURCE Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Terumo Heart, Inc. announced,today that they have ... Drug,Administration (FDA) to begin enrollment in the ... for a Bridge-to-Transplant (BTT) indication., (Logo: ... http://www.newscom.com/cgi-bin/prnh/20080303/CLM012 ), Dr. David Munjal, ...
... 29 Eisai Corporation of,North America, a wholly-owned ... the Food and Drug Administration (FDA) has accepted ... short-term (up to,eight weeks) treatment of gastroesophageal reflux ... indicated that the sNDA will receive,priority review in ...
Cached Medicine Technology:DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial 2FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents 2
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... 12, 2014 Dubai is buzzing with ... is heading to the UAE. The National Basketball ... be in the UAE from 28-31 October to lead ... of diabetes awareness. The event is being organized by ... event management company based in Dubai. The announcement was ...
(Date:7/12/2014)... 12, 2014 Wright & Schulte LLC, an ... Just For Men Lawsuits (case #59776/2014), announces they have ... reports that allege the popular hair dye, Just For Men, ... their face, neck and other areas. In addition to detailing ... chemical burns , the advertisements being run by Wright & ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of special occasion ... Quinceanera dresses . The company’s new items are specially ... paying a large amount of money. They are all ... The company’s online shop has become a one stop ... In addition to exquisite Quinceanera dresses, it also offers ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... Member Adds Operations and Marketing Expertise During a Key ... Growth Period for the Association, ... announced the appointment of Susan Trainer, chief executive,officer and founder, Trainer ... at a pivotal time for the Y, which,is in the middle ...
... While urinary stents and,catheters can be life-saving medical ... infections. With 100 million placed in patients each ... device-associated infections,annually. Nerites Corporation is testing its unique ... from a $100,000 small,business innovation research grant (SBIR) ...
... NASDAQ: CRME TSX: COM, VANCOUVER and DEERFIELD, IL, ... TSX: COM) and its co-development partner,Astellas Pharma US, Inc. ... U.S. Food and Drug Administration (FDA) that a decision ... (NDA) for KYNAPID(TM),(vernakalant hydrochloride). The FDA did not provide ...
... and Drug Administration as a palliative treatment for cancer ... sometimes used off-label for the treatment of peripheral vascular ... American Journal of Therapeutics finds that off-label use of ... adverse events and device malfunctions associated with the use ...
... COVER: "The Party,s Over" (p. 22). Editor-at-Large Evan ... in a precarious state. But the party,s,candidates can ... late to reinvent,the party,s core beliefs," writes Thomas. ... humble mission: to show, in effect, some humility. ...
... million Americans, most of them women, suffer from lupus, ... bodys own tissue. This week marks a significant step ... online publication of four new studies identifying genes involved ... K.Crow, M.D., associate chief of the division of Rheumatology ...
Cached Medicine News:Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 2Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 3Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 4Health News:Cardiome And Astellas Announce Regulatory Update 2Health News:Cardiome And Astellas Announce Regulatory Update 3Health News:Cardiome And Astellas Announce Regulatory Update 4Health News:Study looks at off-label use of biliary stents 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 3Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 4Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 5Health News:NEJM editorial on significance and limitations of new lupus gene expression research 2Health News:NEJM editorial on significance and limitations of new lupus gene expression research 3Health News:NEJM editorial on significance and limitations of new lupus gene expression research 4
... BladderScan® BVI 6100 is a handheld, noninvasive ... is easy to operate, so any staff ... To view ultrasound images from exams and ... records and reimbursement, just log on to ...
... Contigen Bard Collagen Implant, the world's ... implant option for the treatment of Stress ... bulk to surrounding urethral tissue to aid ... with the body's own structure, Contigen Bard ...
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Medicine Products: